94 related articles for article (PubMed ID: 18537149)
1. Factors that restrict the intestinal cell permeation of cyclic prodrugs of an opioid peptide (DADLE): Part I. Role of efflux transporters in the intestinal mucosa.
Ouyang H; Chen W; Andersen TE; Steffansen B; Borchardt RT
J Pharm Sci; 2009 Jan; 98(1):337-48. PubMed ID: 18537149
[TBL] [Abstract][Full Text] [Related]
2. Factors that restrict intestinal cell permeation of cyclic prodrugs of an opioid peptide (DADLE): Part II. Role of metabolic enzymes in the intestinal mucosa.
Ouyang H; Chen W; Andersen TE; Steffansen B; Borchardt RT
J Pharm Sci; 2009 Jan; 98(1):349-61. PubMed ID: 18537150
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the permeation characteristics of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs across the blood-brain barrier using an in situ perfused rat brain model.
Chen W; Yang JZ; Andersen R; Nielsen LH; Borchardt RT
J Pharmacol Exp Ther; 2002 Nov; 303(2):849-57. PubMed ID: 12388672
[TBL] [Abstract][Full Text] [Related]
4. Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides.
Liederer BM; Fuchs T; Vander Velde D; Siahaan TJ; Borchardt RT
J Med Chem; 2006 Feb; 49(4):1261-70. PubMed ID: 16480263
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE.
Tang F; Borchardt RT
Pharm Res; 2002 Jun; 19(6):780-6. PubMed ID: 12134947
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE.
Tang F; Borchardt RT
Pharm Res; 2002 Jun; 19(6):787-93. PubMed ID: 12134948
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the effects of p-glycoprotein inhibitors on the blood-brain barrier permeation of cyclic prodrugs of an opioid peptide (DADLE).
Ouyang H; Andersen TE; Chen W; Nofsinger R; Steffansen B; Borchardt RT
J Pharm Sci; 2009 Jun; 98(6):2227-36. PubMed ID: 18855917
[TBL] [Abstract][Full Text] [Related]
8. Significant differences in the disposition of cyclic prodrugs of opioid peptides in rats and guinea pigs following IV administration.
Liederer BM; Phan KT; Ouyang H; Borchardt RT
J Pharm Sci; 2005 Dec; 94(12):2676-87. PubMed ID: 16258984
[TBL] [Abstract][Full Text] [Related]
9. Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers.
Bak A; Gudmundsson OS; Friis GJ; Siahaan TJ; Borchardt RT
Pharm Res; 1999 Jan; 16(1):24-9. PubMed ID: 9950274
[TBL] [Abstract][Full Text] [Related]
10. Factors that restrict the cell permeation of cyclic prodrugs of an opioid peptide, part 4: Characterization of the biopharmaceutical and physicochemical properties of two new cyclic prodrugs designed to be stable to oxidative metabolism by cytochrome P-450 enzymes in the intestinal mucosa.
Nofsinger R; Borchardt RT
J Pharm Sci; 2012 Sep; 101(9):3500-10. PubMed ID: 22337204
[TBL] [Abstract][Full Text] [Related]
11. A modified coumarinic acid-based cyclic prodrug of an opioid peptide: its enzymatic and chemical stability and cell permeation characteristics.
Ouyang H; Tang F; Siahaan TJ; Borchardt RT
Pharm Res; 2002 Jun; 19(6):794-801. PubMed ID: 12134949
[TBL] [Abstract][Full Text] [Related]
12. In vitro stability and in vivo pharmacokinetic studies of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs.
Yang JZ; Chen W; Borchardt RT
J Pharmacol Exp Ther; 2002 Nov; 303(2):840-8. PubMed ID: 12388671
[TBL] [Abstract][Full Text] [Related]
13. Optimizing oral absorption of peptides using prodrug strategies.
Borchardt RT
J Control Release; 1999 Nov; 62(1-2):231-8. PubMed ID: 10518655
[TBL] [Abstract][Full Text] [Related]
14. Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeation.
Gudmundsson OS; Nimkar K; Gangwar S; Siahaan T; Borchardt RT
Pharm Res; 1999 Jan; 16(1):16-23. PubMed ID: 9950273
[TBL] [Abstract][Full Text] [Related]
15. Factors that restrict the cell permeation of cyclic prodrugs of an opioid peptide, part 3: Synthesis of analogs designed to have improved stability to oxidative metabolism.
Nofsinger R; Fuchs-Knotts T; Borchardt RT
J Pharm Sci; 2012 Sep; 101(9):3486-99. PubMed ID: 22411763
[TBL] [Abstract][Full Text] [Related]
16. Coumarinic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeability.
Gudmundsson OS; Pauletti GM; Wang W; Shan D; Zhang H; Wang B; Borchardt RT
Pharm Res; 1999 Jan; 16(1):7-15. PubMed ID: 9950272
[TBL] [Abstract][Full Text] [Related]
17. Stability of oxymethyl-modified coumarinic acid cyclic prodrugs of diastereomeric opioid peptides in biological media from various animal species including human.
Liederer BM; Borchardt RT
J Pharm Sci; 2005 Oct; 94(10):2198-206. PubMed ID: 16136552
[TBL] [Abstract][Full Text] [Related]
18. The effect of conformation of the acyloxyalkoxy-based cyclic prodrugs of opioid peptides on their membrane permeability.
Gudmundsson OS; Vander Velde DG; Jois SD; Bak A; Siahaan TJ; Borchardt RT
J Pept Res; 1999 Apr; 53(4):403-13. PubMed ID: 10406218
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and conformational analysis of a coumarinic acid-based cyclic prodrug of an opioid peptide with modified sensitivity to esterase-catalyzed bioconversion.
Ouyang H; Vander Velde DG; Borchardt RT; Siahaan TJ
J Pept Res; 2002 Apr; 59(4):183-95. PubMed ID: 11972752
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid peptides using coumarinic acid and phenylpropionic acid linkers.
Wang B; Nimkar K; Wang W; Zhang H; Shan D; Gudmundsson O; Gangwar S; Siahaan T; Borchardt RT
J Pept Res; 1999 Apr; 53(4):370-82. PubMed ID: 10406215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
